尽量减少室内过敏原暴露:什么有效?
Ramin Beheshti1, Torie L Grant2, Robert A Wood2
1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. rbehesh2@jh.edu.
Current allergy and asthma reports
|November 13, 2024
概括
减少室内过敏原,如灰尘和物皮毛是管理过敏性鼻炎和喘的关键. 然而,关于有效的环境控制措施及其临床影响的证据仍然不一致.
科学领域:
- 环境健康 环境健康
- 过敏学 过敏学
- 肺部病理学 肺部病理学
背景情况:
- 室内接触过敏原是导致过敏性鼻炎和喘的重要因素.
- 常见的室内过敏原包括灰尘,物 (猫,狗),动物和.
- 这些过敏原是普遍存在的,并且很难从家庭中消除,这使减少工作复杂化.
研究的目的:
- 审查有关环境控制措施在降低室内过敏原水平方面的有效性证据.
- 评估这些措施对过敏性疾病结果的潜在临床影响.
- 确定减少与室内过敏原有关的过敏性疾病负担的策略.
主要方法:
- 对现有关于室内过敏原环境控制措施的研究进行系统审查.
- 评估有关减少特定室内过敏原 (例如灰尘,物过敏原) 的数据.
- 评估与实施的环境控制策略相关的临床结果.
主要成果:
- 研究表明,关于特定环境控制措施的有效性,结果各不相同.
- 关于降低室内过敏原水平是否直接转化为改善临床结果的证据是混合的.
- 诸如过敏原不透的床铺,空气过和害虫防治等策略的有效性需要进一步调查.
结论:
- 环境控制措施显示了减少室内过敏原暴露的潜力.
- 降低过敏原策略的临床益处需要更一致的证据.
- 需要进一步的研究来优化和验证室内过敏原管理的有效干预措施.
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
Allergic Reactions
27.2K
Overview
27.2K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Drugs Used in Upper Respiratory Disorders: Overview
177
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
177


